title: Leucine-stimulated mTOR signaling is partly attenuated in skeletal muscle of chronically uremic rats.
abstract: The branched-chain amino acid leucine stimulates muscle protein synthesis in part by directly activating the mTOR signaling pathway. Furthermore, leucine, if given in conjunction with resistance exercise, enhances the exercise-induced mTOR signaling and protein synthesis. Here we tested whether leucine can activate the mTOR anabolic signaling pathway in uremia and whether it can enhance work overload (WO)-induced signaling through this pathway. Chronic kidney disease (CKD) and control rats were studied after 7 days of surgically induced unilateral plantaris muscle WO and a single leucine or saline load. In the basal state, 4E-BP1 phosphorylation was modestly depressed in non-WO muscle of CKD rats, whereas rpS6 phosphorylation was nearly completely suppressed. After oral leucine mTOR, S6K1 and rpS6 phosphorylation increased similarly in both groups, whereas the phospho-4E-BP1 response was modestly attenuated in CKD. WO alone activated the mTOR signaling pathway in control and CKD rats. In WO CKD, muscle leucine augmented mTOR and 4E-BP1 phosphorylation, but its effect on S6K1 phosphorylation was attenuated. Taken together, this study has established that the chronic uremic state impairs basal signaling through the mTOR anabolic pathway, an abnormality that may contribute to muscle wasting. However, despite this abnormality, leucine can stimulate this signaling pathway in CKD, although its effectiveness is partially attenuated, including in skeletal muscle undergoing sustained WO. Thus, although there is some resistance to leucine in CKD, the data suggest a potential role for leucine-rich supplements in the management of uremic muscle wasting.
authors.affiliation: Research Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA.
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.forename: Sumita
authors.initials: S
authors.lastname: Sood
authors.forename: Kevin
authors.initials: K
authors.lastname: McIntire
authors.forename: Richard
authors.initials: R
authors.lastname: Roth
authors.forename: Ralph
authors.initials: R
authors.lastname: Rabkin
mesh_terms: D000818:Animals; D002908:Chronic Disease; D004353:Drug Evaluation, Preclinical; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D007930:Leucine / Q000494:pharmacology*; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009135:Muscular Diseases / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*; D014511:Uremia / Q000209:etiology / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D019282:Wasting Syndrome / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D016474:Weight-Bearing / Q000502:physiology
chemical_list: C546845:mTOR protein, rat; D058570:TOR Serine-Threonine Kinases; D007930:Leucine